TABLE 2.

Median symptom score for all treatment groups a different time points relative to enrolment, treatment and last follow-up

	Baseline to last assessment before treatment			Last assessment before treatment to first assessment after treatment			First assessment after treatment to last assessment
	Baseline Median (Q1, Q3)	Last Median (Q1, Q3)	P†	Last Median (Q1, Q3)	First Median (Q1, Q3)	P†	First Median (Q1, Q3)	Last Median (Q1, Q3)	P
None*	4 (2, 7)	6 (2, 10)	<0.001	-	-	-	-	-	-
α-AR	7 (4, 10)	11 (6, 15)	<0.001	11 (7, 15)	12 (6, 17)	0.16	11 (6, 16)	13 (8, 17)	< 0.001
5-ARI	7 (3, 12)	12 (7, 17)	<0.001	10 (6, 16)	10 (6, 15)	0.35	10 (6, 15)	11 (6, 17)	0.03
Vaporization	11 (5, 17)	18 (14, 22)	<0.001	15 (13, 20)	9 (6, 11)	0.001	10 (8, 12)	15 (8, 20)	0.84
TURP	9 (4, 14)	15 (10, 19)	<0.001	16 (11, 19)	6 (2, 10)	<0.0001	7 (2, 12)	8 (3, 13)	0.07

α-ARs, α-adrenergic receptor inhibitors; 5-ARI, 5α-reductase inhibitors; TURP, transurethral resection of the prostate.

^*Median symptom score from baseline to last follow-up assessment.

^†t test P value.